Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy

Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most shorted stocks to buy according to analysts. On February 25, Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted strong financial results for the fourth quarter of 2025, exceeding Wall Street estimates with EPS of $0.80, up from $0.61. Revenue also exceeded expectations, totaling $91.7 million compared to an expected $82.45 million, representing an 11.26% increase.

Following the earnings report, TD Cowen analyst Tyler Van Buren reduced the price target for Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $85 from $120 while maintaining a Buy rating. According to the firm, Soleno experienced a solid Q4, producing $190 million in revenue from just nine months of Vykat XR sales, and ended 2025 financially viable.

Management also maintained a strong commercial trajectory for 2026, with about 1,000 new start forms expected over the next 9-12 months.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases, including Prader-Willi Syndrome.